This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

BioMarin Initiates Phase 3 Trial For BMN 673 For The Treatment Of Metastatic GBRCA Breast Cancer

SAN RAFAEL, Calif., Oct. 31, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that it has dosed the first patient in its Phase 3 program to evaluate BMN 673, its poly ADP-ribose polymerase (PARP) inhibitor, in the treatment of metastatic germline BRCA mutated breast cancer.

"It has been very exciting to work with this novel molecule in the preclinical laboratory where we saw it to be best in class.  It is equally exciting to now be involved in the clinical translation of this drug in this genetically defined population of breast cancer patients who may benefit from a treatment option specifically designed for them," said Dennis Slamon, Ph.D., M.D., Chief, Division Hematology/Oncology and Director of Clinical/Translational Research, Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at the University of California, Los Angeles.  "Oncology therapy is moving towards a personalized and targeted model with the goal of establishing more effective treatments based on an individual's genetic profile, and BMN 673 could be an important step toward tailoring cancer treatments by tumor type."

"Enrolling the first patient is an important milestone in the clinical trial process. We are excited to be part of a trial that not only offers the potential to eliminate the use of chemotherapy, but also the possibility of improving the length and quality of life for patients already diagnosed with hereditary breast cancer," said Fran Visco, President of the National Breast Cancer Coalition.

The Phase 3 study is an open-label, randomized, parallel, two-arm, multi-center study of BMN 673 versus physician's choice in approximately 430 germline BRCA mutation patients with locally advanced and/or metastatic breast cancer, who have received no more than two prior chemotherapy regimens for metastatic disease. The primary objective of the study is to measure progression free survival (PFS). Secondary objectives include evaluating the objective response rate (ORR) and the overall survival (OS). 

"We are eager to fully enroll this important trial for breast cancer patients with hereditary breast cancer to better understand the role of BMN 673 in this defined population," said Hank Fuchs, M.D., Chief Medical Officer of BioMarin. "We are looking forward to gaining a better understanding of the safety and efficacy of our compound."

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,070.40 +46.34 0.26%
S&P 500 2,114.49 +6.20 0.29%
NASDAQ 5,016.9290 +11.5380 0.23%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs